3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Neoplasms
13
Venous Thromboembolism
11
Venous Thrombosis
4
Multiple Myeloma
3
Upper Extremity Deep Vein Thrombosis
2
Thrombosis
2
Pulmonary Embolism
2
Lung Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Thromboembolism
1
Stomach Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Prevention of Venous Thromboembolism
1
Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery
1
Pancreatic Neoplasms
1
Lymphoma
1
Leukemia
1
Inflammation
1
Immune System Diseases
1
Hemorrhage
1
Hematologic Neoplasms
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Dyskinesias
1
Interventions
Gemcitabine
92
Cisplatin
70
Oxaliplatin
37
Capecitabine
37
durvalumab
29
Fluorouracil
26
pembrolizumab
24
Leucovorin
22
S 1 (combination)
18
Nivolumab
13
Irinotecan
13
Bevacizumab
13
lenvatinib
12
tremelimumab
10
apatinib
8
Trastuzumab
7
Injections
7
Albumin-Bound Paclitaxel
7
130-nm albumin-bound paclitaxel
7
Paclitaxel
6
Immune Checkpoint Inhibitors
6
Docetaxel
6
titanium silicide
5
surufatinib
5
envafolimab
5
camrelizumab
5
atezolizumab
5
Folfox protocol
5
Drug Therapy
5
Carboplatin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Biliary Tract Neoplasms
×
Rivaroxaban
×
Clear all
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled